---
layout: default
title: Ceftriaxone
parent: 僅模型預測 (L5)
nav_order: 200
evidence_level: L5
indication_count: 7
---

# Ceftriaxone
{: .fs-9 }

證據等級: **L5** | 預測適應症: **7** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ceftriaxone: From Bacterial Infections to Polyclonal Hyperviscosity Syndrome

## One-Sentence Summary

Ceftriaxone is a third-generation cephalosporin antibiotic, broadly used against bacterial infections (no original-indication text was returned in this evidence pack's Malaysia registration records, so this is inferred from the drug's known class and the mechanistic notes embedded in the evidence). The TxGNN model's top-ranked prediction for this candidate is **Polyclonal Hyperviscosity Syndrome**, but this direction is currently supported by **0 clinical trials** and **0 publications**, and the evidence pack's own mechanistic assessment flags it as biologically implausible.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in the Malaysia (NPRA) registration data provided — license records returned empty indication fields and no original indication list was included in this evidence pack |
| Predicted New Indication | Polyclonal Hyperviscosity Syndrome |
| TxGNN Prediction Score | 99.39% |
| Evidence Level | L5 |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 28 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for ceftriaxone was not returned as a structured field in this evidence pack (flagged as a High-severity data gap). However, the pack's own repurposing rationale describes ceftriaxone as a third-generation cephalosporin whose mechanism is inhibition of bacterial cell wall synthesis — consistent with its known role as a broad-spectrum antibacterial agent.

Polyclonal hyperviscosity syndrome, by contrast, is a plasma-cell/immunoglobulin pathology (excess circulating immunoglobulins increasing blood viscosity), a disease process unrelated to bacterial cell wall synthesis. The evidence pack's own mechanistic assessment for this prediction explicitly states there is no known biological link between ceftriaxone's antibacterial action and this condition, and characterizes the high TxGNN score as most likely a knowledge-graph association artifact rather than a mechanistically grounded hypothesis.

In short: this specific top-ranked prediction lacks both mechanistic plausibility and any corroborating clinical or literature evidence. It should be treated as a model-only signal, not a repurposing hypothesis ready for further evaluation.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Malaysia Market Information

NPRA records confirm ceftriaxone is marketed in Malaysia with 28 active licenses, but this data extract did not return individual license details (authorization numbers, product names, dosage forms, and approved-indication text were all blank for the records retrieved). A separate query against NPRA is needed to populate license-level detail.

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: retrieval of TFDA/NPRA package-insert warnings and contraindications is marked as a Blocking data gap in this evidence pack — this must be resolved before any formal S1 safety assessment can proceed.)*

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (Polyclonal Hyperviscosity Syndrome) has no clinical trial or literature support and no mechanistic rationale connecting an antibacterial cell-wall-synthesis inhibitor to an immunoglobulin-mediated hyperviscosity disorder — the evidence pack's own assessment characterizes this as a likely knowledge-graph artifact rather than a genuine repurposing signal.

**To proceed, the following is needed:**
- TFDA/NPRA package insert warnings and contraindications (currently a Blocking gap — required before any safety review)
- Confirmed mechanism-of-action documentation for ceftriaxone (currently a High-severity gap)
- Individual NPRA license details (product names, dosage forms, approved indications) rather than the blank records returned here
- If this candidate is to be pursued further, independent mechanistic or preclinical evidence connecting cephalosporin activity to hyperviscosity pathophysiology

**Separate note:** this evidence pack contains six other predicted indications for ceftriaxone. Rank 4 ("infectious otitis media") carries substantially stronger evidence (Evidence Level L2, 3 clinical trials including RCTs, 19 publications, recommendation "Proceed with Guardrails") and is a more credible candidate for near-term evaluation — it likely warrants its own separate report rather than being folded into this one.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

